Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.
Impactful Shortlisted Abstracts/Publications in TNBC
Chairpersons :
Dr. S. S. Nirni, Dr. Boman Dhabhar
Speaker :
Dr. Mounika Boppana